Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor
• * Inoperable or metastatic disease
• Failed standard therapy
• Confirmed cancer antigen (CanAg) expression
• * Patients must have non-colorectal cancer or pancreatic cancer
• * Tumor must have a homogeneous pattern (i.e., staining present in \> 75% of tumor cells for CanAg) and are 2+ or 3+ intensity by immunohistochemistry \* No known leptomeningeal disease or progressive brain disease
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy ≥ 12 weeks
• Absolute neutrophil count ≥ 1,500/mm³
• Hemoglobin ≥ 9 g/dL (transfusion allowed)
• Platelet count ≥ 100,000/mm³
• aPTT and INR ≤ 1.5 times upper limit of normal (ULN)
• Creatinine ≤ 1.5 mg/dL
• Creatinine clearance ≥ 60 mL/min
• Bilirubin ≤ 1.5 mg/dL
• AST and ALT \< 2.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 30 days after completion of study treatment
• No hypersensitivity to agents of the same class as the study drug, humanized or nonhumanized antibodies, or immunoconjugates
• No active, uncontrolled infection
• No hepatitis B surface antigen or hepatitis C antibody positivity
• No history of alcoholic liver disease
• No serious medical or psychiatric disorder that would preclude compliance with study requirements
• No peripheral neuropathy \> grade 1
• No other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage A low-grade prostate cancer
• No severe concurrent disease or condition that, in the opinion of the investigator, would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Recovered from prior therapy
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C)
• At least 4 weeks since prior radiotherapy, immunotherapy, or hormone therapy for cancer
• At least 4 weeks since prior major surgery
• No concurrent chemotherapy, other immunotherapy, radiotherapy, or other investigational therapy
• * Palliative radiotherapy for related bone metastases allowed
• No other concurrent anticancer therapy